Tag Archives: faux

Bayh-Dole Basics, 4: contractor comments

Bayh-Dole defines anyone on the other side of a funding agreement from a federal agency as a contractor.  The term is arbitrary and misleading. Let’s look at both aspects. The standard patent rights clause requires the contractors that host federally … Continue reading

Posted in Bayh-Dole | Tagged , , , , , , , , , | Comments Off on Bayh-Dole Basics, 4: contractor comments

Bayh-Dole’s Public Covenant, 4

The Faux Public Covenant in Bayh-Dole The government license forms an essential part of the public covenant on inventions arising from research or development supported in part by government funding. For the other parts of the public covenant, the patent … Continue reading

Posted in Bayh-Dole | Tagged , , , | Comments Off on Bayh-Dole’s Public Covenant, 4

The Biddle Report’s Perfectly Fine Assumptions

From time to time, I revisit territory. I wrote about this issue almost two years ago, now. I provide here a different angle that gets at the same point. Here’s Sean O’Connor proposing that a flawed assumption in the U.S. … Continue reading

Posted in Bayh-Dole, History, Policy, Stanford v Roche | Tagged , , , , , | Comments Off on The Biddle Report’s Perfectly Fine Assumptions

A New Guide to Bayh-Dole–Outline Version

Here’s an alternative guide to Bayh-Dole and its doppleganger faux Bayh-Dole. There’s a whole book in here, but I’ve left out the chapter and verse documentation and the historical evidence and interviews and the like. This is not the version … Continue reading

Posted in Bayh-Dole | Tagged , , | Comments Off on A New Guide to Bayh-Dole–Outline Version

The NIH’s complicity in faux Bayh-Dole and high drug prices

Here’s “A ’20-20′ View of Invention Reporting to the National Institutes of Health”–published by the NIH in 1995. 2. WHAT IS THE BAYH-DOLE ACT AND WHY IS IT IMPORTANT? The Bayh-Dole Act encourages researchers to patent and market their inventions … Continue reading

Posted in Bayh-Dole, History, Stanford v Roche | Tagged , , , , | Comments Off on The NIH’s complicity in faux Bayh-Dole and high drug prices

Senator Bayh’s inventor-loathing faux Bayh-Dole Act

There has been plenty written about the practice lesson taught by the Supreme Court decision in Stanford v Roche. I’m dismayed how much of it shows no evidence of an awareness of the facts of the case and the primary … Continue reading

Posted in Bayh-Dole, Policy, Stanford v Roche | Tagged , , , , , | 1 Comment